BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

PHASE2,PHASE3

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Nektar Therapeutics made the decision to discontinue the bempegaldesleukin program based on three negative studies. SFJ Pharmaceuticals, Inc. and Nektar Therapeutics, in consultation with the study IDMC, have decided to discontinue PROPEL-36.

Conditions

Metastatic Head and Neck Cancer
Recurrent Head and Neck Cancer

Interventions

DRUG: Bempegaldesleukin
DRUG: Pembrolizumab

Sponsor

Nektar Therapeutics

Collaborators

[object Object]
[object Object]